Results 71 to 80 of about 3,494,819 (252)

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

BEAST log files for Leave-one-out-cross-validation

open access: yes, 2016
Example BEAST log files for Leave-one-out-cross-validation analysis and additional files to plot results using the "PlotLOOCV" function using the R-package TipDatingBeast.
Camilo Khatchikian (3191880)   +1 more
core   +1 more source

Iterative Approximate Cross-Validation

open access: yes, 2023
Cross-validation (CV) is one of the most popular tools for assessing and selecting predictive models. However, standard CV suffers from high computational cost when the number of folds is large. Recently, under the empirical risk minimization (ERM) framework, a line of works proposed efficient methods to approximate CV based on the solution of the ERM ...
Yuetian Luo, Zhimei Ren, Rina Barber
openaire   +3 more sources

Subtype‐specific enhancer RNAs define transcriptional regulators and prognosis in breast cancers

open access: yesMolecular Oncology, EarlyView.
This study employed machine learning methodologies to perform the subtype‐specific classification of RNA‐seq data sets, which are mapped on enhancers from TCGA‐derived breast cancer patients. Their integration with gene expression (referred to as ProxCReAM eRNAs) and chromatin accessibility profiles has the potential to identify lineage‐specific and ...
Aamena Y. Patel   +6 more
wiley   +1 more source

Cross-validation results (mean AUROC [standard deviation AUROC]) of GBT models using 10-fold cross-validation.

open access: yes, 2022
Cross-validation results (mean AUROC [standard deviation AUROC]) of GBT models using 10-fold cross-validation.
Shaodong Wang (8825291)   +7 more
core   +1 more source

Cross-Validation of Surface Reflectance Between GF5-02 AHSI and EnMAP Across Diverse Land Cover Types

open access: yesRemote Sensing
Multi-source hyperspectral data are increasingly applied in environmental monitoring, precision agriculture, and geological exploration, yet differences in sensor characteristics hinder interoperability.
Shuhan Liu   +8 more
doaj   +1 more source

Cross-Validation Model Averaging for Generalized Functional Linear Model

open access: yesEconometrics, 2020
Functional data is a common and important type in econometrics and has been easier and easier to collect in the big data era. To improve estimation accuracy and reduce forecast risks with functional data, in this paper, we propose a novel cross ...
Haili Zhang, Guohua Zou
doaj   +1 more source

Pre‐analytical optimization of cell‐free DNA and extracellular vesicle‐derived DNA for mutation detection in liquid biopsies

open access: yesMolecular Oncology, EarlyView.
Pre‐analytical handling critically determines liquid biopsy performance. This study defines practical best‐practice conditions for cell‐free DNA (cfDNA) and extracellular vesicle–derived DNA (evDNA), showing how processing time, storage conditions, tube type, and plasma input volume affect DNA integrity and mutation detection.
Jonas Dohmen   +11 more
wiley   +1 more source

Cross-validation of DES model.

open access: yes, 2022
Cross-validation of DES model.
Caiwang Tai (12506662)   +6 more
core   +1 more source

Effects of long-time series of data on genetic evaluations for performance of Swedish Warmblood riding horses

open access: yesAnimal, 2010
For Swedish Warmblood sport horses, breeding values (BVs) are predicted using a multiple-trait animal model with results from competitions and young horse performance tests.
Å. Viklund   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy